Caribou Biosciences’ CEO on working toward a pivotal trial in 2nd line LBCL
- blonca9
- Sep 6, 2023
- 1 min read
Rachel Haurwitz describes recent data and the durability profile of Caribou’s allogeneic CAR-T product as the company plans to discuss a pivotal trial design with FDA.